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ABSTRACT
Objective: To explore the degree of agreement between
patient- and clinician-reported outcomes (PROs and CROs,
respectively) in three chronic diseases.
Methods: Respectively, 120, 131, and 61 French general
practitioners (GPs) included 291, 307, and 90 patients with
chronic venous disease (CVD), irritable bowel syndrome
(IBS), and peripheral arterial occlusive disease (PAOD), in a
cross-sectional survey. Patients completed a speciﬁc Health-
Related Quality of Life (QoL) questionnaire (Chronic
Venous Insufﬁciency Questionnaire [CIVIQ], Functional
Digestive Disorders Quality of Life [FDDQL], and Claudi-
cation Scale [CLAU-S], respectively) and scored their pain
(visual analog scale, pain-free walking distance). GPs were
concomitantly asked to estimate patients’ pain and QoL.
Results: Although correlated (CVD and IBS: Kw = 0.27 and
Kw = 0.31, respectively; PAOD: r = 0.64, P < 0.01), pain
intensity estimated by GPs was lower than as estimated by
patients with CVD and IBS (e.g., 39.0 ± 24.9 vs. 30.4 ± 21.0
for IBS), and pain-free walking distance was greater as esti-
mated by GPs than by patients with PAOD. Pain estimated
by patients only partially reﬂected their QoL (r between 0.30
and 0.78; P between 0.02 and <0.01). Global QoL scores
estimated by patients and GPs were moderately correlated
(Kw between 0.17 and 0.28). GPs underestimated QoL
impairment in CVD (global score: 72 ± 19 vs. 61 ± 20) and
in most dimensions of the IBS questionnaire (in six of eight
dimensions), and overestimated QoL impairment in PAOD
(54 ± 21 vs. 66 ± 23).
Conclusions: Although correlated, PROs and CROs dif-
fered. In addition, their relationship was not consistent
across diseases. PROs are therefore essential to take account
of all the aspects of diseases.
Keywords: chronic venous disease, Chronic Venous Insufﬁ-
ciency Questionnaire, Claudication Scale, Functional Diges-
tive Disorders Quality of Life, Health-Related Quality of
Life, irritable bowel syndrome, peripheral arterial occlusive
disease.
Introduction
It is nowadays generally agreed [1] that health consists
in “a state of complete physical, mental and social
well-being, not merely the absence of disease and inﬁr-
mity” [2]. Physicians, researchers, and regulators
therefore need to procure the information needed for
them to be in a position to assess the impact of a dis-
ease on the patient’s daily life and its mode of man-
agement, that is, what Schipper et al. [3] deﬁned as
quality of life related to state of health.
Information generally passes orally from patient to
doctor during consultation. For more than 20 years
now, however, advances in psychometrics and decision
analysis have enabled the development of scientiﬁc
tools measuring the impact of a disease and its man-
agement as perceived by the patient. Such so-called
health-related quality of life (QoL) scales or question-
naires may be generic or disease-speciﬁc. The generic
instruments can be used in a wide range of situations
and are especially useful for comparing the differential
QoL impact of pathologies [4]. Speciﬁc instruments
can only be used for one given pathology, but they are
more change-sensitive than generic instruments and
more relevant to the assessment of treatment effects
[4]. Nevertheless, all of these kinds of instruments are
still little used, and the impact of many chronic pathol-
ogies on patients’ QoL is often underestimated or
hardly, if at all, taken into account in assessing drug
effectiveness [5].
It thus seemed worth measuring the degree of agree-
ment between QoL as perceived by patients and meas-
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ured on QoL scales and that estimated by their general
practitioner (GP) on consultation. Three disabling
chronic pathologies, frequently encountered in general
practice and each belonging to a different medical
ﬁeld, were selected: chronic venous disease (CVD) [6],
irritable bowel syndrome (IBS) [7,8], and peripheral
arterial occlusive disease (PAOD) at the intermittent
claudication stage [9]. A French-version QoL question-
naire existed for each of these at the time of the study
[10–14].
Patients and Methods
Study Design and Patients
This cross-sectional study, which collected data on
QoL and pain, was carried out in France between
October 2002 and July 2003, with the participation of
urban GPs. All GPs included were members of the
Thalès Medical Observation Center [15,16] and rou-
tinely used the Doc’Ware software package (2002,
Version 5.1d, BKL Consultant, France) to which an
extra question page could be added to detail certain
points regarding patient management.
Spontaneously consulting adult patients known by
their regular GPs to present with chronic venous or
veno-lymphatic disease [17], IBS [18], or lower limb
arterial disease at the intermittent claudication (stage II
according to Fontaine and Leriche’s classiﬁcation) [19]
were included in the study if: 1) they gave their consent;
2) they were able to ﬁll in a self-administered question-
naire; or 3) they did not receive for at least a month a
medical treatment for their disease. Patients presenting
with current serious diseases (e.g., progressive cancer,
severe cardiac insufﬁciency) were excluded.
At the end of each consultation with an included
patient, the GP ﬁlled out an extra question page espe-
cially designed for the study, and then handed the
patient the QoL questionnaire matching the diagnosis.
The patients ﬁlled out the questionnaire themselves at
home and posted it to the Thalès Medical Observation
Center.
Patient Questionnaires
The Chronic Venous Insufﬁciency Questionnaire
(CIVIQ) is a CVD-speciﬁc QoL questionnaire devel-
oped and validated in France [10]. It comprises 20
items along four dimensions: physical (four items),
pain (four items), social (three items), and psycholog-
ical (nine items). On each item, ﬁve responses are pro-
posed (5-point Likert scale). Scores were calculated as
per the user manual, except insofar as the global score
and the scores on the four dimensions were subjected
to a linear transformation to give response values lying
between 0 (bad QoL) and 100 (good QoL), to make
the results easier to grasp.
The Functional Digestive Disorders Quality of Life
scale (FDDQL) is a speciﬁc questionnaire for IBS and
dyspepsia developed and validated in French, English,
and German [11,12]. It comprises 43 items along eight
dimensions: daily activities (eight items), anxiety (ﬁve
items), diet (six items), sleep (three items), discomfort
(nine items), coping with disease (six items), control of
disease (three items), and stress (three items). Patients
choose one of ﬁve responses per item (5-point Likert
scale). Scores were calculated as per the user manual, by
adding up the item scores so as to give global and
dimension scores from 0 (bad QoL) to 100 (good QoL).
The Claudication Scale (CLAU-S) is a dedicated
intermittent claudication questionnaire developed and
validated in German, then translated into French, and
revalidated as such [13,14]. It comprises 47 items
along ﬁve dimensions: daily living (9 items), pain (10
items), social life (4 items), disease-speciﬁc anxiety (13
items), and mood (11 items). Patients choose one of
four or ﬁve responses per item (4- or 5-point Likert
scale) except for one question which rates pain inten-
sity on a visual analog scale (VAS) graduated from 0 to
10. After readjustment as per the user manual, global
and dimension scores ranged from 0 (bad QoL) to 100
(good QoL).
The CVD and IBS patients were also required to
answer a question about the intensity of pain experi-
enced over the previous two weeks, on a VAS going
from 0 (no pain) to 10 (severe pain). VAS values were
then subjected to a transformation to give values lying
between 0 and 100. PAOD patients had to specify the
distance (in meters) at which pain started when
walking.
Computerized Extra Question Page (Filled out by GPs)
Depending on whether the patient was suffering from
CVD, IBS, or PAOD, the extra question page com-
prised four, eight, or ﬁve questions corresponding to
the label of the four, eight, or ﬁve dimensions of the
CIVIQ, FDDQL, and CLAU-S questionnaires, respec-
tively. Responses ranged from 0 to 10 for CVD, and 0
to 5 for IBS and PAOD. Linear transformation pro-
duced scores lying between 0 (bad QoL) and 100 (good
QoL) per question. A global score (average of each
dimension score) was then calculated, lying between 0
(bad QoL) and 100 (good QoL). The GPs also esti-
mated patients’ pain, on a VAS from 0 (no pain) to 10
(severe pain) for CVD and IBS, and in terms of pain-
free walking distance (in meters) for PAOD.
Statistical Analysis
The Thalès Medical Observation Center performed the
statistical analyses, using the SAS software package,
Version 8.2 (1999–2001, SAS Institute, Cary, NC,
USA). For each pathology, pain intensity according to
patients and to GPs, pain intensity and QoL scores
according to patients, and QoL scores according to
patients and GP estimates of patient QoL, respectively,
were compared by regression, analysis of variance
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(ANOVA), or using weighted Kappa (Kw) correlation
coefﬁcients. For regression and ANOVA, the signiﬁ-
cance threshold was set at 0.05. Missing QoL ques-
tionnaire data were replaced as per the user manual.
Ethical Considerations
The study did not alter patient management and there-
fore was not declared or submitted to ethical commit-
tee approval, in line with current French legislation.
Patients who agreed to take part, on the other hand,
were informed of their rights under the Informatique
et Libertés law on protection of information.
Results
Patients
In all, 291 CVD, 307 IBS, and 90 PAOD patients were
recruited by 120, 131, and 61 GPs, respectively. The
CVD patients were overwhelmingly female (80.8%),
with a mean age (±SD) of 60.3 ± 15.6 years. The IBS
patients were also mainly female (64.3%), with a mean
age of 57.5 ± 16.1 years. The PAOD patients, on the
other hand, were generally male (70.0%), aged
72.0 ± 10.9 years. Many patients presented with
comorbidity—notably high blood pressure (32.6%,
24.1%, and 51.1% of CVD, IBS, and PAOD cases,
respectively) or hyperlipidemia (29.9%, 26.1%, and
55.6%, respectively). Twenty-one percent of the
PAOD patients were diabetic, and 30% suffered from
angina or had a history of myocardial infarction.
Questionnaire Response Rate and Quality
The response rate for the QoL questionnaires was
good: 240 of the 291 patients suffering from CVD
(82.5%), 239 of the 307 patients suffering from IBS
(77.9%), and 68 of the 90 patients suffering from
PAOD (75.6%) ﬁlled out the questionnaires. The
response quality for the QoL questionnaires was very
good: 216 of the 240 (90.0%), 229 of the 239
(95.8%), and 60 of the 68 (88.2%) CIVIQ, FDDQL,
and CLAU-S questionnaires, respectively, had less than
four missing items, and 169 (70.4%), 211 (88.3%),
and 38 (55.9%) were complete. GP responses to the
extra question page were equally satisfactory, being
complete for 276 (94.8%), 211 (68.7%), and 81
(90%) CVD, IBS, and PAOD patients, respectively.
Pain Intensity According to Patients and GPs
Overall, pain was rated as more intense by patients
than by their GPs in case of CVD and IBS (Table 1). In
CVD, patient- and GP-rated pain correlated moder-
ately (Kw = 0.27): the greater the pain according to the
patient, the greater the pain according to his or her GP.
GPs, however, underestimated pain, in particular in
those patients they deemed less affected (i.e., with the
lowest GP pain ratings) (Fig. 1). IBS results were sim-
ilar (Table 1). PAOD patients claimed to experience
pain as of 431 ± 711 m, compared with 880 ± 1734 m
according to their GPs. This result indicated that,
although their responses were greatly variable, the GPs
overestimated the pain-free walking distance and
therefore underestimated the pain perceived by the
patients. There was a signiﬁcant correlation between
the GP-estimated pain-free walking distance and that
stated by the patients (r = 0.64, P < 0.01): the shorter
the pain-free walking distance according to the patient,
the shorter that estimated by the GP.
QoL Score and Patient-Estimated Pain Intensity
In CVD and IBS, global QoL scores correlated signif-
icantly with patient-assessed pain intensity (r = 0.78
and r = 0.71, respectively; P < 0.01) (Table 2): global
QoL score fell (indicating reduced QoL) as pain inten-
sity rose. In IBS, QoL scores varied by as much as 60
on a scale of 100 for a given pain intensity (Fig. 2),
suggesting that pain intensity only partially reﬂected
Table 1 Pain intensity assessed by patients and general practi-
tioners. Relationship between patients’ and general practitioners’
pain scores
Disease Patients
General 
practitioners
Relationship 
between the two
assessments*
Chronic venous disease (CVD)†
Number of data 233 291 233‡
Mean ± SD 42.2 ± 24.9 29.7 ± 19.2 Kw = 0.27
Irritable bowel syndrome (IBS)†
Number of data 232 307 232‡
Mean ± SD 39.0 ± 24.9 30.4 ± 21.0 Kw = 0.31
Peripheral arterial occlusive disease (PAOD)§
Number of data 68 90 68‡
Mean ± SD 431 ± 711 880 ± 1734 r = 0.64 (P < 0.01)
*The relationship between patients’ and GPs’ scores was analyzed using weighted
Kappa coefﬁcient (CVD, IBS) or a regression (PAOD).
†Pain intensity was assessed using a visual analog scale, ranging from 0 (no pain) to
100 (severe pain).
‡Number of (paired patient + GP) data.
§Pain intensity was assessed by means of the pain-free walking distance (m).
Figure 1 General practitioners (GPs) underestimated pain in patients
suffering from chronic venous disease (CVD). All values under the equality
line indicate GP underestimation of pain.
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QoL. CVD results were similar. In PAOD, the QoL/
pain-free walking distance correlation was weak (r =
0.30, P = 0.02), making it impossible to afﬁrm that
global QoL scores increased (indicating better QoL)
with the pain-free walking distance.
QoL Scores According to Patients and GPs
Overall, CVD patients considered their QoL more
adversely affected than did their GP (Table 3). In con-
trast, in case of PAOD, the GPs deemed the patients’
QoL more badly affected than did the patients them-
selves (Table 3). In IBS, ﬁnally, global scores were sim-
ilar for GPs and patients, but differences emerged
according to the dimension: GPs underestimated the
impact of the disease on the dimensions of diet, sleep,
discomfort, coping with disease, control of disease,
and stress, and overestimated it on the daily activities
and anxiety dimensions (Table 3). The correlation
Table 2 Quality of life (QoL) global scores and pain intensity
according to patients. Relationship between the two parameters
Disease
QoL global
score*
Pain 
intensity†
Relationship between
the two parameters‡
Chronic venous disease (CVD)
Number of data 240 233 233§
Mean ± SD 60.9 ± 20.3 42.2 ± 24.9 r = 0.78 (P < 0.01)
Irritable bowel disease (IBS)
Number of data 239 232 232§
Mean ± SD 57.4 ± 15.4 39.0 ± 24.9 r = 0.71 (P < 0.01)
Peripheral arterial occlusive disease (PAOD)
Number of data 68 68 68§
Mean ± SD 66.2 ± 22.9 431 ± 711 r = 0.30 (P = 0.02)
*QoL global scores were assessed by the CIVIQ, FDDQL, and CLAU-S question-
naires for CVD, IBS, and PAOD, respectively. QoL scores ranged between 0 (bad
QoL) and 100 (good QoL).
†Pain intensity was assessed using a visual analog scale, ranging from 0 (no pain) to
100 (severe pain) for CVD and IBS, and pain-free walking distance (m) for PAOD.
‡The relationship between the two parameters was analyzed using a regression; the
correlation coefﬁcient r assessed the quality of the relationship.
§Number of (paired patient + GP) data.
Figure 2 Patient-estimated pain intensity partially reﬂected quality of life
(QoL) estimated by patients suffering from irritable bowel syndrome
(IBS). The regression line shows global QoL score variation per pain inten-
sity value.
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Table 3 Quality of life (QoL) scores (mean ± SD) according to patients and general practitioners. Relationship between patients’ and
general practitioners’ QoL scores
Patients General practitioners Relationship between scores
Chronic venous disease (CVD)*
Number of data 240 291 240†
Global score 60.9 ± 20.3 72.4 ± 18.6 Kw = 0.17‡
Physical dimension 56.3 ± 25.4 69.3 ± 22.2 P < 0.01§
Pain dimension 55.3 ± 20.1 70.0 ± 19.9 P < 0.01§
Social dimension 62.5 ± 23.9 75.6 ± 21.0 P = 0.08§
Psychological dimension 64.9 ± 22.9 74.1 ± 21.1 P = 0.03§
Irritable bowel syndrome (IBS)*
Number of data 239 307 239†
Global score 57.4 ± 15.4 59.2 ± 19.0 Kw = 0.28‡
Daily activities dimension 71.6 ± 21.2 57.8 ± 25.4 P < 0.01§
Anxiety dimension 62.5 ± 22.2 53.6 ± 28.0 P < 0.01§
Diet dimension 56.4 ± 22.6 60.0 ± 26.2 P < 0.01§
Sleep dimension 66.1 ± 20.3 72.4 ± 25.8 P < 0.01§
Discomfort dimension 51.0 ± 18.2 69.0 ± 25.2 P < 0.01§
Coping with disease dimension 54.6 ± 19.8 57.2 ± 26.4 P < 0.01§
Control of disease dimension 55.3 ± 22.8 59.0 ± 26.2 P < 0.01§
Stress dimension 31.5 ± 24.8 42.8 ± 26.6 P < 0.01§
Peripheral arterial occlusive disease (PAOD)*
Number of data 68 90 58†
Global score 66.2 ± 22.9 53.6 ± 20.8 Kw = 0.26‡
Daily living dimension 57.4 ± 27.8 47.0 ± 27.0 P = 0.14§
Pain dimension 64.5 ± 20.2 55.0 ± 21.4 P = 0.07§
Social life dimension 75.6 ± 17.9 57.4 ± 26.2 P = 0.02§
Disease-speciﬁc anxiety dimension 64.9 ± 27.9 56.2 ± 26.0 P < 0.01§
Mood dimension 72.3 ± 23.8 63.0 ± 27.8 P < 0.01§
*QoL was assessed by the CIVIQ, FDDQL, and CLAU-S questionnaires for CVD, IBS, and PAOD, respectively (patients) and by computerized extra question pages (GPs). QoL
scores ranged from 0 (bad QoL) to 100 (good QoL).
†Number of (patient–physician pairs) data available for the regression, all the available data were included in the analysis of variance.
‡The relationship between QoL scores was analyzed using weighted Kappa coefﬁcients.
§The relationship between QoL scores was analyzed using an analysis of variance.
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between patient and GP estimates of QoL global score
was moderate: Kw = 0.17, Kw = 0.28, and Kw = 0.26,
for CVD, IBS, and PAOD, respectively (Table 3).
Figures 3–5, respectively, present patients’ mean
QoL scores in relation to the corresponding GP QoL
estimates for the CIVIQ pain dimension, the FDDQL
control of disease dimension, and the CLAU-S daily
living dimension. These ﬁgures can be taken as repre-
sentative of all of the dimensions of these three ques-
tionnaires: the GPs underestimating (Fig. 3) and
overestimating (Fig. 5) disease impact on patient QoL,
and total disagreement as to QoL between patients and
GPs (Fig. 4).
In CVD, GPs underestimated disease impact on
QoL in patients they considered as enjoying a good
QoL on the physical dimension (Fig. 3). Similar results
were found for the pain and psychological dimensions.
On the CIVIQ social dimension, irrespective of GP rat-
ings, patients’ mean QoL scores were all very similar
and not statistically different from the mean score of
those patients rated 0 by their GP, suggesting that
patients and GPs had utterly discrepant perceptions of
the disease’s impact on the social dimension.
In IBS, GPs overestimated disease impact on QoL
on the daily activities dimension. On the diet dimen-
sion, they overestimated disease impact on QoL in
those patients they esteemed to have poor QoL and
underestimated disease impact on QoL in those
patients they esteemed to have good QoL. On the con-
trol of disease dimension, irrespective of GP ratings,
patients’ mean QoL scores were all very similar and
not statistically different from the mean score of those
patients rated 0 by their GP, suggesting that patients
and GPs had utterly discrepant perceptions of the dis-
ease’s impact on this dimension (Fig. 4). Findings were
similar on the FDDQL dimensions of anxiety, sleep,
discomfort, coping with disease, and stress.
In PAOD, GPs overestimated disease impact on
QoL on the daily living dimension in patients they con-
sidered to enjoy poorer QoL (Fig. 5). Findings were
similar on the dimensions of pain, social life, and dis-
ease-speciﬁc anxiety. On the mood dimension, irre-
spective of GP ratings, patients’ mean QoL scores were
all very similar and not statistically different from the
mean score of those patients rated 0 by their GP, sug-
gesting that patients and GPs had utterly discrepant
perceptions of the disease’s impact on this dimension.
Discussion
The present study sought to investigate agreement
between patient and GP estimates of QoL and pain
experienced. Three disabling chronic pathologies
(CVD, IBS, and PAOD), for which a French-version
Figure 3 Pain dimension of the Chronic Venous Insufﬁciency Question-
naire (CIVIQ): General practitioners (GPs) underestimated the impact of
chronic venous disease (CVD) on patients’ quality of life (QoL). QoL was
assessed by patients by means of the CIVIQ [10]. All values under the
equality line indicate GPs’ underestimation of the impact of CVD on QoL.
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Figure 5 Daily living dimension of the Claudication Scale (CLAU-S):
General practitioners (GPs) overestimated the impact of peripheral arte-
rial occlusive disease (PAOD) on patients’ quality of life (QoL). QoL was
assessed by patients by means of the CLAU-S [13,14].  All values above the
equality line indicate GPs’ overestimation of the impact of PAOD on QoL.
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Figure 4 Control of disease dimension of the Functional Digestive Dis-
orders Quality of Life (FDDQL): General practitioners (GPs) were unable
to estimate the impact of irritable bowel syndrome (IBS) on patients’ qual-
ity of life (QoL). QoL was assessed by patients by means of the FDDQL
[11,12].  The equality line shows discrepancies between patients and GPs.
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
QoL score (GPs)
Qo
L 
sc
or
e 
(p
ati
en
ts)
QoL mean score (±std)
Equality line (Y=X)
Good QoL 
Good QoL 
Chassany et al.44
QoL questionnaire existed at the time of the study,
were selected [6–14].
The ﬁrst ﬁnding is that GPs correctly identiﬁed
those patients who were suffering the least and the
most, but systematically underestimated the pain expe-
rienced. Second, it emerged that QoL scores and
patient-estimated pain intensity correlated signiﬁ-
cantly, but that the intensity of the pain experienced by
the patients was only a partial reﬂection of their QoL.
In CVD and IBS patients, QoL scores varied widely for
any given level of pain. In PAOD, moreover, the cor-
relation was quite weak, and it was not possible to
afﬁrm that global QoL scores fell as the walking-dis-
tance threshold for onset of pain grew shorter. Like-
wise, Marquis et al. [20], validating the ARTEMIS
QoL questionnaire dedicated to intermittent claudica-
tion, found walking test and QoL scores to be indeed
related, but that QoL scores varied widely for pain-free
walking distances shorter than 1000 m. Third, it was
found that the QoL of the patients was diminished
even though they were being followed by their GPs
without any medical treatment; these patients were
thus presumably deemed by their GPs not to require
any such management. Finally, it was shown that GPs
underestimated the QoL impact of CVD and IBS. On
the other hand, GPs overestimated the QoL impact of
PAOD. It further appeared that GPs did not have a
very good idea of which QoL dimensions were affected
by which pathology. This was especially true as
regards IBS, where the global FDDQL score was close
to GP estimates, but completely illogical discrepancies
emerged on all of the individual dimensions, including
those that might be supposed to be easy to assess, such
as diet and sleep.
The limitations inherent in this kind of cross-
sectional study, regarding GPs, patients, and method-
ology, might be thought to account for some of the
discrepancies between patient and GP judgments.
There may indeed be some question as to whether the
GPs taking part in the present study were truly repre-
sentative of French GPs as a whole. The experience of
Thalès Medical Observation Center, however, allays
this doubt [15,16]. There may also be some question as
to whether the patients included in the present study
were truly representative of those suffering from the
three pathologies. Nevertheless, although slightly older
than those recruited for the validation of the CIVIQ,
FDDQL, and CLAU-S questionnaires, our patients
showed characteristics broadly similar to those in pre-
vious studies [6–14,21–26]. Furthermore, although it
is admittedly difﬁcult to compare QoL scores between
studies (there being few publications, and with differ-
ences in how the scores are presented and also between
the populations studied), it nevertheless remains that
the QoL scores of our patients agree with those gen-
erally found on the same questionnaires in other
reports [11,14,27]. Finally, concerning the methodol-
ogy, it may be asked whether the question page pro-
vided on the software for the GPs was sufﬁciently
precise, with just one question per dimension. The
CIVIQ, FDDQL, and CLAU-S questionnaires were all
developed as patient-reported outcome (PRO) instru-
ments, and could not be used directly by the GPs. The
questions retained for each pathology had to mimic
questions that could be routinely used by the GPs
during consultation. The choice of a single question,
focusing on the main concept of each dimension of
each questionnaire, was adopted to allow comparison,
and for reasons of feasibility. The questionnaire incor-
porated into the software had to be short (four to eight
questions) if the GPs were not to be put off: otherwise,
lack of time would probably mean that they would ﬁll
it in incompletely if at all. The appropriateness of a
short questionnaire was indeed borne out by the good
response rate.
Thus, the differences found between the GPs’ and
the patients’ judgments of pain and QoL are to be
accounted for by the GPs’ difﬁculty in getting to under-
stand the problems encountered by the patient in rela-
tion to his or her disease—especially when it is difﬁcult
to speak about a topic during consultation: it is doubt-
less easier for a patient to talk about the problems that
lower limb pain causes in everyday life than to speak
about their fear of having ﬂatulence in public. It would
seem that the GPs were relying on their medical knowl-
edge and on the clinical signs in assessing their
patients’ QoL: they were better at estimating the inten-
sity of pain than QoL itself, doubtless because pain is
directly linked to clinical signs, unlike QoL, which is a
more complex matter. Moreover, they overestimated
the QoL impact of PAOD, an organic affection with
serious consequences, but underestimated that of the
two functional pathologies. As far as IBS and CVD
were concerned, the QoL dimensions the GPs had the
best grasp of were those directly relating to the impair-
ment: physical and pain dimensions in the case of
CVD, daily activities and diet in that of IBS. In PAOD,
in contrast, dimensions directly relating to functional
impairment, such as daily Living and pain, were mis-
judged by the GPs. This is undoubtedly due to the fact
that, in PAOD, the pain-free walking distance and the
pain experienced do not impact QoL directly, but
rather alter the patients’ behavior, which in turn ends
up affecting the QoL [14]. The present study was only
descriptive and was not able to go further in analyzing
these differences in judgment between GPs and
patients. It would certainly have been of interest to try
to identify the patient proﬁles (e.g., in terms of age,
sex, depression) for which the GPs had a better or
poorer grasp of QoL.
In conclusion, clinicians’ and patients’ perspectives,
although overlapping to some extent, differed. Clini-
cians tended to underestimate the intensity of the pain
experienced by their patients. The pain experienced
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could not therefore be accurately inferred from the cli-
nician’s point of view. Similarly, the patient’s percep-
tion of pain did not fully reﬂect the impact on QoL. In
addition, clinicians tended to underestimate or overes-
timate QoL impairment in patients, probably relying
on the inherent severity of the disease as perceived by
the medical community (e.g., functional vs. organic
diseases). These results demonstrate that PROs are
essential for taking account of all the aspects of disease
[28].
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